Menu

Research director at INSERM, head of the team « Physiopathology of dependence and relapse » Inserm unit 952/ CNRS UMR7224, Université Pierre et Marie Curie, Paris VI.
He is also President of scientific advisory board of MILDT. Member of scientific committee of the European Observatory of Drugs and Toxicomanies.
He is Laureate for the Prize of the European College of Neurospsychopharmacology (September 2009) for his work and new hypothesis of neurobiological mechanisms of addiction.

About us

Kinnov Therapeutics is dedicated to the R&D of innovative therapies against addiction.
Supported by experienced scientists in the drug discovery and development, we have identified the key receptors of addiction. KT-110, our first-in-class lead composition, enters phase 2 clinical trial for alcohol addiction.